Epigenetic‐modifying therapies: An emerging avenue for the treatment of inflammatory skin diseases

Experimental Dermatology - Tập 30 Số 8 - Trang 1167-1176 - 2021
Julie Z. Yi1, Jean S. McGee1,2
1Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA

Tóm tắt

AbstractEpigenetic modifications include DNA methylation, histone modification and the action of microRNAs. These mechanisms coordinate in complex networks to control gene expression, thereby regulating key physiological processes in the skin and immune system. Recently, researchers have turned to the epigenome to understand the pathogenesis of inflammatory skin diseases. In psoriasis and atopic dermatitis, epigenetic modifications contribute to key pathogenic events such as immune activation, T‐cell polarization and keratinocyte dysfunction. These discoveries have introduced new possibilities for the treatment of skin diseases; unlike genetics, epigenetic alterations are readily modifiable and potentially reversible. In this viewpoint essay, we summarize the current state of epigenetic research in inflammatory skin diseases and propose that targeting the histone machinery is a promising avenue for the development of new therapies for psoriasis and atopic dermatitis. Expanding on the progress that has already been made in the field of cancer epigenetics, we discuss existing epigenetic‐modifying tools that can be applied to the treatment of inflammatory skin diseases and consider future directions for investigation in order to allow for the widespread clinical application of such therapies.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra072067

10.1126/science.1191078

10.1038/nrg2005

10.1056/NEJMra1805035

10.1080/13543784.2017.1291630

Schcolnik‐Cabrera A, 2018, Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine‐valproate versus vorinostat‐decitabine incutaneous t‐cell lymphoma in HUT78 cells, Am J Blood Res, 8, 5

10.1093/jnci/djj447

10.2174/138920106778521523

10.1016/j.critrevonc.2006.07.010

10.3389/fimmu.2019.00678

10.3389/fcell.2020.00071

10.1586/1744666X.2015.1020301

10.1016/j.immuni.2013.08.009

10.1096/fj.05-5360com

10.1182/blood-2006-04-019711

10.1073/pnas.0400567101

10.1084/jem.20180520

10.1038/s41423-019-0315-0

10.1016/B978-0-12-800957-4.00006-0

10.1111/imm.12058

10.1038/nri2487

10.1016/j.jaci.2018.07.014

10.3389/fimmu.2020.01105

10.1038/nature15252

10.2147/JIR.S129027

10.1111/1346-8138.13806

10.1080/1744666X.2016.1212660

10.1289/ehp.1205412

10.1038/ng.3985

10.1016/j.jaci.2018.10.010

10.1038/s12276-019-0305-4

10.1177/2050312115578317

10.1111/cea.12108

10.1016/j.jaci.2017.11.018

10.1016/j.jaci.2013.06.036

10.1038/jid.2011.348

10.1016/j.jaut.2013.01.001

10.1038/jid.2015.128

10.1016/j.jid.2015.12.029

10.1186/s13148-018-0541-9

10.1007/s00403-013-1432-8

10.1016/j.bbrc.2012.04.128

10.1007/s00109-005-0020-6

10.4049/jimmunol.1403196

10.1111/j.1365-2133.2008.08505.x

10.1016/j.jdermsci.2018.06.001

10.1111/j.1365-4632.2006.02962.x

10.1684/ejd.2011.1383

10.1016/j.jdermsci.2010.07.011

10.1093/jmcb/mjv022

10.1016/j.jaci.2019.10.015

10.1038/jid.2014.87

10.1038/s41598-020-74798-z

10.1111/ced.12206

10.1111/j.1398-9995.2011.02760.x

10.1111/j.0022-202X.2005.23925.x

10.1158/1078-0432.CCR-15-1435

10.1016/j.jid.2017.02.980

10.7164/antibiotics.47.301

10.7164/antibiotics.47.315

10.1006/excr.1998.4027

10.1182/blood.V98.9.2865

10.1200/JCO.2010.28.9066

10.1200/JCO.2006.10.2434

10.1182/blood-2006-06-025999

10.4049/jimmunol.173.6.4171

10.1111/j.1365-2222.2004.02006.x

10.1182/blood-2010-05-284711

10.1073/pnas.052702999

10.1111/j.1365-2567.2007.02678.x

10.1189/jlb.0708401

Chung YL, 2004, Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy, Mol Cancer Ther, 3, 317, 10.1158/1535-7163.317.3.3

10.1016/j.jaci.2016.03.050

10.1038/s41385-019-0135-7

10.1016/j.jaci.2020.02.007

10.1016/j.jaci.2019.04.027

10.1016/j.jid.2017.04.031

10.5021/ad.2012.24.2.168

10.1111/j.1398-9995.2006.01151.x

10.1007/s00403-011-1136-x

10.1038/ncomms8454

10.1038/jid.2011.139

10.1038/jid.2015.82

10.1038/jid.2008.179

10.1371/journal.pone.0142081

10.1016/j.phrs.2015.06.001

10.1073/pnas.1501956112

10.1016/j.intimp.2010.08.004

10.1111/cea.13244

10.1016/S1470-2045(16)30375-8

10.1016/j.yjmcc.2018.01.009

10.1007/s40264-018-0773-9

10.1172/jci.insight.120880

10.1158/2326-6066.CIR-15-0077-T

10.18632/oncotarget.17950

10.1093/annonc/mds591

10.1038/sj.emboj.7601012

Thông tin
Thông tin xuất bản

Experimental Dermatology

Tập 30 Số 8

1167-1176

Thông tin tác giả